Jennison Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-3,100,864
| Closed | -$25.2M | – | 646 |
|
|
2019
Q1 | $25.2M | Sell |
3,100,864
-697,989
| -18% | -$5.68M | 0.03% | 322 |
|
|
2018
Q4 | $30.7M | Sell |
3,798,853
-51,150
| -1% | -$413K | 0.03% | 282 |
|
|
2018
Q3 | $29.4M | Buy |
3,850,003
+378,565
| +11% | +$2.89M | 0.03% | 340 |
|
|
2018
Q2 | $19.9M | Sell |
3,471,438
-33,157
| -0.9% | -$190K | 0.02% | 402 |
|
|
2018
Q1 | $16.7M | Buy |
3,504,595
+422,360
| +14% | +$2.01M | 0.02% | 411 |
|
|
2017
Q4 | $15.1M | Buy |
3,082,235
+5,774
| +0.2% | +$28.4K | 0.01% | 434 |
|
|
2017
Q3 | $16.1M | Buy |
3,076,461
+995,643
| +48% | +$5.22M | 0.02% | 430 |
|
|
2017
Q2 | $11.6M | Buy |
2,080,818
+236,182
| +13% | +$1.31M | 0.01% | 461 |
|
|
2017
Q1 | $15.5M | Buy |
1,844,636
+489,536
| +36% | +$4.11M | 0.02% | 451 |
|
|
2016
Q4 | $8.58M | Buy |
1,355,100
+3,770
| +0.3% | +$23.9K | 0.01% | 485 |
|
|
2016
Q3 | $5.96M | Sell |
1,351,330
-4,972
| -0.4% | -$21.9K | 0.01% | 497 |
|
|
2016
Q2 | $3.85M | Sell |
1,356,302
-1,302
| -0.1% | -$3.7K | ﹤0.01% | 497 |
|
|
2016
Q1 | $3.84M | Buy |
1,357,604
+9,041
| +0.7% | +$25.6K | ﹤0.01% | 494 |
|
|
2015
Q4 | $13.9M | Buy |
1,348,563
+24,014
| +2% | +$248K | 0.01% | 455 |
|
|
2015
Q3 | $15.1M | Buy |
1,324,549
+6,832
| +0.5% | +$77.9K | 0.02% | 463 |
|
|
2015
Q2 | $19.7M | Buy |
1,317,717
+344,618
| +35% | +$5.15M | 0.02% | 456 |
|
|
2015
Q1 | $8.79M | Buy |
+973,099
| New | +$8.79M | 0.01% | 492 |
|
|
2014
Q4 | – | Sell |
-321,422
| Closed | -$3.14M | – | 714 |
|
|
2014
Q3 | $3.14M | Buy |
321,422
+480
| +0.1% | +$4.7K | ﹤0.01% | 539 |
|
|
2014
Q2 | $4.09M | Sell |
320,942
-37,615
| -10% | -$480K | ﹤0.01% | 504 |
|
|
2014
Q1 | $3.79M | Buy |
358,557
+1,205
| +0.3% | +$12.8K | ﹤0.01% | 526 |
|
|
2013
Q4 | $2.72M | Sell |
357,352
-92,648
| -21% | -$704K | ﹤0.01% | 543 |
|
|
2013
Q3 | $3.28M | Buy |
+450,000
| New | +$3.28M | ﹤0.01% | 528 |
|